Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UroGen PharmaLTS:0XOD +1.13%54 Return-on-Tangible-Asset is -22.68% as of Jun. 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 54/100 and a GF Value™ of $24.88 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,415 Biotechnology companies, UroGen Pharma ranks worse than 65.87% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. UroGen Pharma's annualizedNet Income for the quarter that ended in Jun. 2026 was $-57.4 Mil. UroGen Pharma's average total tangible assets for the quarter that ended in Jun. 2026 was $253.1 Mil. Therefore, UroGen Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -22.68%.
The historical rank and industry rank for UroGen Pharma's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0XOD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -91.68 Med: -66.94 Max: -9.15
Current: -44.36
During the past 11 years, UroGen Pharma's highest Return-on-Tangible-Asset was -9.15%. The lowest was -91.68%. And the median was -66.94%.
LTS:0XOD's Return-on-Tangible-Asset is ranked worse than 65.87% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs LTS:0XOD: -44.36
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
UroGen Pharma Return-on-Tangible-Asset Related Terms
UroGen Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0XOD vs PVLA, AUPH, RAPP: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, UroGen Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -22.68% mean?
UroGen Pharma (LTS:0XOD) has a Return-on-Tangible-Asset of -22.68% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #932 out of 1415 companies in the Biotechnology industry, placing it in the top 65.9%.
Is UroGen Pharma's Return-on-Tangible-Asset too high?
UroGen Pharma's current Return-on-Tangible-Asset is -22.68%. Based on the distribution chart, UroGen Pharma ranks #932 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Return-on-Tangible-Asset compare to PVLA and AUPH?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #932 out of 1415 companies for Return-on-Tangible-Asset. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Return-on-Tangible-Asset is -22.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.88, compared to a current price of $47.41 — trading 90.6% above its estimated fair value. The current Return-on-Tangible-Asset is -22.68%. UroGen Pharma's overall GF Score™ is 54/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Return-on-Tangible-Asset is -22.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $47.41 is trading 90.6% above its estimated GF Value™ of $24.88.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
Return-on-Tangible-Asset: -22.68%
GF Value™: $24.88 vs. price of $47.41 (90.6% above fair value)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
54GF Score
Get the complete analysis for LTS:0XOD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
